Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $42.7 million.

  • UNITED THERAPEUTICS's Change in Accured Expenses fell 5.45% to $31.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.7 million, marking a year-over-year increase of 50.80%. This contributed to the annual value of $42.7 million for FY2024, which is 25.22% down from last year.
  • Per UNITED THERAPEUTICS's latest filing, its Change in Accured Expenses stood at $42.7 million for FY2024, which was down 25.22% from $57.1 million recorded in FY2023.
  • In the past 5 years, UNITED THERAPEUTICS's Change in Accured Expenses ranged from a high of $57.1 million in FY2023 and a low of -$12.5 million during FY2021.
  • For the 3-year period, UNITED THERAPEUTICS's Change in Accured Expenses averaged around $48.1 million, with its median value being $44.5 million (2022).
  • In the last 5 years, UNITED THERAPEUTICS's Change in Accured Expenses plummeted by 132.38% in 2021 and then skyrocketed by 456.00% in 2022.
  • MRY analysis of 5 years shows UNITED THERAPEUTICS's Change in Accured Expenses stood at $38.6 million in 2020, then crashed by 132.38% to -$12.5 million in 2021, then skyrocketed by 456.00% to $44.5 million in 2022, then increased by 28.31% to $57.1 million in 2023, then decreased by 25.22% to $42.7 million in 2024.
  • Its last three reported values are $42.7 million in FY2024, $57.1 million for FY2023, and $44.5 million during FY2022.